TAG:
laboratory testing
Monitoring Patients on Opioids with Toxicology Screens Is Opportunity for Clinical Labs
By Mary Van Doren | From the Volume XXVI No. 13 – September 23, 2019 Issue
This is an excerpt of a 2,883-word article in the Sept. 23, 2019 issue of THE DARK REPORT (TDR). The full article is available to members of The Dark Intelligence Group. CEO SUMMARY: In this first industry briefing on such a program, THE DARK REPORT exp…
Lab Monitors Compliance of Chronic Opioid Patients
By Joseph Burns | From the Volume XXVI No. 13 – September 23, 2019 Issue
CEO SUMMARY: Hospitals and health systems developing programs to manage patients on chronic opioid therapy (COT) are finding that an essential element of these programs is regular toxicology testing. In its role as the toxicology test provider for a health network in Indiana, AIT Laborato…
Monitoring Patients on Opioids Is Opportunity for Clinical Labs
By Joseph Burns | From the Volume XXVI No. 13 – September 23, 2019 Issue
CEO SUMMARY: When developing a program to identify and treat patients who misused opioids or needed chronic opioid therapy, Community Health Network (CHN) of Indianapolis recognized that clinical lab toxicology tests were one of the few sources of objective data about patient compliance….
In New Mexico, Three Collaborators Improve Patient Care, Outcomes
By Joseph Burns | From the Volume XXVI No. 11 – August 12, 2019 Issue
IT’S OFFICIAL! A YEAR-LONG COLLABORATION involving a health insurer, a clinical laboratory, and an analytics company showed that insurers and physicians can use clinically-actionable intelligence developed from medical lab test data to improve patient outcomes. This important accomplishment in patie…
What Have We Done for You Lately?
By R. Lewis Dark | From the Volume XXVI No. 5 – April 8, 2019 Issue
Our Editor-In-Chief just finished the daunting task of confirming 125 speakers for more than 80 sessions for our 24th annual Executive War College on Lab and Pathology Management. It is our biggest conference ever! These facts are significant to you for an important reason. The planning pha…
COLA: GAO Should Address PAMA’s Effect on Patients
By Joseph Burns | From the Volume XXVI No. 4 – March 18, 2019 Issue
CEO SUMMARY: In a recent statement, COLA, an organization that accredits clinical labs, expressed strong concern about how a report from the Government Accountability Office did not address how the Protecting Access to Medicare Act of 2014 (PAMA) affects patients’ access to testing, esp…
Fla. Blue Cross Contract May Be Next Battleground
By Joseph Burns | From the Volume XXVI No. 4 – March 18, 2019 Issue
CEO SUMMARY: In Florida, the Blue Cross Blue Shield contract is coming up for renewal and the question is whether it will renew as exclusive to one national lab company. But Florida is not the only state where BCBS plans are planning to issue new contracts. Among the Blues plans that may …
PAMA Price Cuts Reduce Revenue at LabCorp, Quest
By Joseph Burns | From the Volume XXVI No. 3 – February 25, 2019 Issue
This story was updated from the original on March 27, 2019, and includes corrected information in three places. CEO SUMMARY: In their respective earnings reports for the fourth quarter and the full year of 2018, executives at both Laboratory Corporation of America and Quest Diagno…
PAMA Price Cuts Reduce Revenue at Two National Labs
By Mary Van Doren | From the Volume XXVI No. 3 – February 25, 2019 Issue
This is an excerpt from a 1,500-word article in the Feb. 25, 2019 issue of THE DARK REPORT. The full article is available to members of The Dark Intelligence Group. CEO SUMMARY: In their respective earnings reports for the fourth quarter and the full year of 2018, executives at both La…
Lower Prices, More Data in UHC’s New Lab Network?
By Joseph Burns | From the Volume XXVI No. 2 – February 4, 2019 Issue
CEO SUMMARY: It’s been a common strategy among managed care payers to seek the lowest prices for clinical laboratory testing when negotiating contracts with labs. However, lower prices may become less important over time as the health system moves away from fee-for-service payment towar…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized